Company: ABUS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001447028-25-000083
Chunk: 108

Company: Arbutus Biopharma Corp
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 108
---
 industry, market and economic trends to corroborate the Company’s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the contingent consideration liability that would result from changes in the significant assumptions. We also involved our valuation specialists to assist us in evaluating the valuation methodology and the discount rate. 

/s/ Ernst & Young LLP 

We have served as the Company's auditor since 2019.

Philadelphia, Pennsylvania

March 27, 2025

 76

ARBUTUS BIOPHARMA CORPORATION

Consolidated Balance Sheets

(Expressed in thousands of US Dollars, except share and per share amounts)

 December 31, 2024December 31, 2023Assets  Current assets:  Cash and cash equivalents$36,330 $26,285 Investments in marketable securities, current86,293 99,718 Accounts receivable2,409 1,776 Prepaid expenses and other current assets2,284 4,248 Total current assets127,316 132,027 Property and equipment, net of accumulated depreciation3,309 4,674 Investments in marketable securities, non-current— 6,284 Right of use asset1,048 1,416 Other non-current assets34 — Total assets$131,707 $144,401 Liabilities and stockholders' equity Current liabilities:  Accounts payable and accrued liabilities$7,564 $10,271 Deferred license revenue, current7,571 11,791 Lease liability, current483 425 Total current liabilities15,618 22,487 Liability related to sale of future royalties4,829 6,953 Deferred license revenue, non-current2,863 — Contingent consideration10,225 7,600 Lease liability, non-current806 1,343 Total liabilities34,341 38,383 Stockholders’ equityCommon shares Authorized: unlimited number without par value  Issued and outstanding: 189,963,492 and 169,867,414 as of December 31, 2024 and 2023, respectively. 1,410,025 1,349,821 Additional paid-in capital82,048 81,270 Deficit(1,346,572)(1,276,652)Accumulated other comprehensive loss(48,135)(48,421)Total stockholders' equity